ions.bio provides an all-in-one solution for biomarker development, utilizing mass spectrometry and AI-driven bioinformatics to transform clinical samples into validated multi-omics datasets. This approach streamlines the biomarker discovery process, reducing the time and risk associated with drug and diagnostics development for biotech and pharmaceutical companies.
Funding
Funding not disclosed
Founders
Product
Problem
Biomarker development is a time-intensive and high-risk process, often creating bottlenecks in drug and diagnostics development. Traditional methods struggle to efficiently translate clinical samples into validated multi-omics datasets, hindering scientific breakthroughs.
Solution
ions.bio offers an integrated solution for biomarker discovery, providing comprehensive services from biosample collection to data analysis. The company leverages advanced mass spectrometry for multi-omics data generation, coupled with AI-enhanced bioinformatics for data analysis. This streamlined approach aims to accelerate the identification, validation, and implementation of biomarkers, reducing the time and risk associated with traditional biomarker development. By offering the entire biomarker discovery value chain, ions.bio empowers researchers to unlock the full potential of biomarkers for diagnostics and therapeutic development.
Target Audience
ions.bio primarily serves biotech and pharmaceutical companies involved in diagnostics and drug development.
Features
- End-to-end biomarker discovery value chain, from sample collection to data analysis
- Biosample collection services ensuring efficient and reliable collection of high-quality biosamples at any scale
- Cutting-edge mass spectrometry-based multi-omics for accurate and reproducible data
- Proprietary software solutions to optimize data acquisition and knowledge extraction from mass spectrometry data
- Advanced bioinformatics and statistical analysis to generate meaningful insights from complex datasets
- Biomarker validation using multiple large-scale cohorts and extensive quality control
- Development of ready-to-use assays for reliable biomarker monitoring in high-throughput